Last 12 months
Inside the activity.
2 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 13, 2025 10:06 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 5 | $3.40 | $17.00 |
DisclosureSEC source: 0001104659-25-059106 · tm2517905-2_4seq1.xml · nonDerivative · entry 4 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 354,625 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F3 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 10:06 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 3 | $3.40 | $10.20 |
DisclosureSEC source: 0001104659-25-059106 · tm2517905-2_4seq1.xml · nonDerivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 207,419 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F3 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 06:01 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 2 | $3.40 | $6.80 |
DisclosureSEC source: 0001104659-25-059091 · tm2517905-1_4seq1.xml · nonDerivative · entry 13 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 125,330 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F3 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 06:01 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 5 | $3.40 | $17.00 |
DisclosureSEC source: 0001104659-25-059091 · tm2517905-1_4seq1.xml · nonDerivative · entry 10 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 409,291 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F3 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 06:01 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 1 | $3.40 | $3.40 |
DisclosureSEC source: 0001104659-25-059091 · tm2517905-1_4seq1.xml · nonDerivative · entry 7 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II NT, LP Disclosed balance after: 54,791 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F3 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 06:01 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 5 | $3.40 | $17.00 |
DisclosureSEC source: 0001104659-25-059091 · tm2517905-1_4seq1.xml · nonDerivative · entry 4 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 354,625 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F3 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 06:01 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 3 | $3.40 | $10.20 |
DisclosureSEC source: 0001104659-25-059091 · tm2517905-1_4seq1.xml · nonDerivative · entry 1 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 207,419 F2 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F3 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F4 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 2,199 | $3.03 | $6,662.97 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 15 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 125,332 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 7,180 | $3.03 | $21,755.40 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 12 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 409,296 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 961 | $3.03 | $2,911.83 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 9 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II NT, LP Disclosed balance after: 54,792 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 6,221 | $3.03 | $18,849.63 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 6 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 354,630 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 3,639 | $3.03 | $11,026.17 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 3 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 207,422 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 2,199 | $3.03 | $6,662.97 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 15 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 125,332 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 7,180 | $3.03 | $21,755.40 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 12 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 409,296 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 961 | $3.03 | $2,911.83 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 9 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II NT, LP Disclosed balance after: 54,792 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 6,221 | $3.03 | $18,849.63 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 6 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 354,630 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 29, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 3,639 | $3.03 | $11,026.17 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 3 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 207,422 F3 · price: The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 1,632 | $2.87 | $4,683.84 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 14 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 127,531 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 5,332 | $2.87 | $15,302.84 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 11 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 416,476 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 714 | $2.87 | $2,049.18 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 8 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II NT, LP Disclosed balance after: 55,753 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 4,620 | $2.87 | $13,259.40 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 5 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 360,851 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 2,702 | $2.87 | $7,754.74 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 2 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 211,061 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 1,632 | $2.87 | $4,683.84 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 14 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 127,531 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 5,332 | $2.87 | $15,302.84 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 11 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 416,476 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 714 | $2.87 | $2,049.18 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 8 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II NT, LP Disclosed balance after: 55,753 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 4,620 | $2.87 | $13,259.40 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 5 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 360,851 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 28, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 2,702 | $2.87 | $7,754.74 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 2 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 211,061 F2 · price: The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 2,290 | $3.05 | $6,984.50 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 13 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 129,163 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 7,478 | $3.05 | $22,807.90 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 10 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 421,808 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 1,000 | $3.05 | $3,050.00 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 7 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II NT, LP Disclosed balance after: 56,467 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 6,479 | $3.05 | $19,760.95 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 4 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 365,471 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 30, 2025 01:55 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 3,790 | $3.05 | $11,559.50 |
DisclosureSEC source: 0001104659-25-054422 · tm2516511-2_4seq1.xml · nonDerivative · entry 1 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 213,763 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 2,290 | $3.05 | $6,984.50 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 13 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 129,163 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 7,478 | $3.05 | $22,807.90 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 10 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 421,808 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 1,000 | $3.05 | $3,050.00 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 7 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II NT, LP Disclosed balance after: 56,467 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 6,479 | $3.05 | $19,760.95 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 4 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I, LP Disclosed balance after: 365,471 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:53 UTC |
Kreis Leslie W.10% owner
Cavu Management, LP10% owner
Cavu Advisors, LLC10% owner
BP Directors, LP10% owner
|
SaleCommon Stock | 3,790 | $3.05 | $11,559.50 |
DisclosureSEC source: 0001104659-25-054421 · tm2516511-1_4seq1.xml · nonDerivative · entry 1 Kreis Leslie W. · CIK 0001813316 · 10% owner Cavu Management, LP · CIK 0001813270 · 10% owner Cavu Advisors, LLC · CIK 0001813310 · 10% owner BP Directors, LP · CIK 0001813311 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund I QP, LP Disclosed balance after: 213,763 F1 · price: The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. F4 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F5 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F6 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:15 UTC |
KEYSER D JEFFREYDirector
|
OtherSeries A Warrants · Derivative | 3,832 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001493152-24-029238 · ownership.xml · derivative · entry 2 KEYSER D JEFFREY · CIK 0001393516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,832 shares Expires 2024-07-25 F1 · kind: On July 24, 2024, the Reporting Person exercised a Series A Warrant to purchase 3,832 shares of common stock at an exercise price of $3.13 per share. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:15 UTC |
KEYSER D JEFFREYDirector
|
OtherCommon stock | 3,832 | $3.13 | $11,994.16 |
DisclosureSEC source: 0001493152-24-029238 · ownership.xml · nonDerivative · entry 1 KEYSER D JEFFREY · CIK 0001393516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On July 24, 2024, the Reporting Person exercised a Series A Warrant to purchase 3,832 shares of common stock at an exercise price of $3.13 per share. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC |
SHARMA PANNADirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028187 · ownership.xml · derivative · entry 1 SHARMA PANNA · CIK 0001157989 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options will vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC |
Chandru VijayDirector
|
GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028183 · ownership.xml · derivative · entry 2 Chandru Vijay · CIK 0001813367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-07-15 F2 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC |
Chandru VijayDirector
|
GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028183 · ownership.xml · derivative · entry 1 Chandru Vijay · CIK 0001813367 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC |
Margrave David R.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028186 · ownership.xml · derivative · entry 1 Margrave David R. · CIK 0001813162 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC |
Silberstein David S.Director
|
GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028188 · ownership.xml · derivative · entry 2 Silberstein David S. · CIK 0001812659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-07-15 F2 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC |
Silberstein David S.Director
|
GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028188 · ownership.xml · derivative · entry 1 Silberstein David S. · CIK 0001812659 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:30 UTC |
Bhatia Kishor G.Chief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028182 · ownership.xml · derivative · entry 1 Bhatia Kishor G. · CIK 0001812638 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC |
Maccecchini Maria-LuisaDirector
|
GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028185 · ownership.xml · derivative · entry 1 Maccecchini Maria-Luisa · CIK 0001315018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options will vest and first become exercisable in equal monthly increments over a 36-month period commencing August 15, 2024. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:30 UTC |
KEYSER D JEFFREYDirector
|
GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001493152-24-028184 · ownership.xml · derivative · entry 1 KEYSER D JEFFREY · CIK 0001393516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing August 15, 2024. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:30 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 4,253 | $6.33 | $26,921.49 |
DisclosureSEC source: 0001104659-24-065616 · tm2415690-1_4seq1.xml · nonDerivative · entry 8 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II, LP Disclosed balance after: 131,453 F2 · price: The price reported in Column 4 is a weighted average price. On May 24, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $6.15 to $6.64 inclusive. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F4 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
| May 24, 2024 Filed May 28, 2024 20:30 UTC |
Fletcher Aaron G.L.10% owner
BIOS Fund I, LP10% owner
BIOS Fund I QP, LP10% owner
BIOS Fund II, LP10% owner
BIOS Fund II QP, LP10% owner
BIOS Fund II NT, LP10% owner
Bios Equity Partners, LP10% owner
Bios Equity Partners II, LP10% owner
BIOS Capital Management, LP10% owner
BIOS Advisors GP, LLC10% owner
|
SaleCommon Stock | 13,888 | $6.33 | $87,911.04 |
DisclosureSEC source: 0001104659-24-065616 · tm2415690-1_4seq1.xml · nonDerivative · entry 6 Fletcher Aaron G.L. · CIK 0001789490 · 10% owner BIOS Fund I, LP · CIK 0001697316 · 10% owner BIOS Fund I QP, LP · CIK 0001700297 · 10% owner BIOS Fund II, LP · CIK 0001714576 · 10% owner BIOS Fund II QP, LP · CIK 0001716869 · 10% owner BIOS Fund II NT, LP · CIK 0001728851 · 10% owner Bios Equity Partners, LP · CIK 0001813314 · 10% owner Bios Equity Partners II, LP · CIK 0001813313 · 10% owner BIOS Capital Management, LP · CIK 0001813845 · 10% owner BIOS Advisors GP, LLC · CIK 0001813844 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Bios Fund II QP, LP Disclosed balance after: 429,286 F2 · price: The price reported in Column 4 is a weighted average price. On May 24, 2024 each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $6.15 to $6.64 inclusive. F3 · ownership.nature: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Leslie W. Kreis, Jr and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management. F4 · ownership.nature: Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities. F5 · ownership.nature: For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.